GlobeNewswire Inc | Dec 17, 2020 07:00AM EST

December 17, 2020

SAN FRANCISCO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema or Olema Oncology, NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced that Sean P. Bohen, M.D., Ph.D., president and chief executive officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021, at 10 a.m. Eastern Time.

The presentation and Q&A session will be webcast live from the Investors & Media section of Olemas website. A replay of the webcast will be available.

About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers. Olemas lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

ContactsInvestor Contact:ir@olema.com

Media Contact:Sheryl Seapy, W2Osseapy@w2ogroup.com949-903-4750